Hanmi's new bio drug 'Rolvedon' sales 88%↑ in the US mkt
By Son, Hyung Min | translator Hong, Ji Yeon
24.11.15 05:00:40
가나다라
0
Recorded the sales of KRW 21 billion in Q3…rebounded since Q4 of 2023
Has completed the Phase 1 clinical trial for the same-day administration…will present the data at the U.S. conference next month
The U.S. sales of Rolvedon (Korean product name: Rolontis) have substantially increased. Hanmi Pharmaceutical's U.S. partnering company, Assertio, plans to expand market share by securing Rolvedon's indication for the same-day administration.
According to Assertio on Novermber 14, Rolveron's sales in the U.S. market in Q3 were US$ 15 million (about KRW 21 billion), up 87.5% Year-over-Year (YoY). Rolvedon has recorded cumulative sales of US$110.30 million (about KRW 155 billion) since its launch in Q4 of 2022.
Rolvedon is a treatment for neutropenia developed by Hanmi Pharmaceutical. It is Korea's 33rd new drug, approved in March 2021. After that, Hanmi Pharmaceutical and its U.S. partnering
Son, Hyung Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)